Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cisplatin + Olaparib |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
| Olaparib | Lynparza | AZD2281|KU-0059436 | PARP Inhibitor (Pan) 29 | Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for treatment of ERBB2 (HER2)-negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, ovarian cancer with deleterious or suspected deleterious germline BRCA mutations and received 3 or more prior therapies, metastatic pancreatic adenocarcinoma with deleterious or suspected deleterious germline BRCA mutations as a maintenance therapy, metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations who progressed following enzalutamide or abiraterone, in combination with abiraterone in patients with mCRPC harboring deleterious or suspected deleterious BRCA mutations, as a maintenance therapy in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and in epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutation, and in combination with Avastin (bevacizumab) as maintenance therapy in HDR defective epithelial ovarian, fallopian tube or primary peritoneal cancer as defined by deleterious or suspected deleterious BRCA mutation, and/or genomic instability (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BARD1 G491R | breast cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 G491R was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 V85M | breast cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 V85M was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| FANCA Q1307Sfs*6 | hepatocellular carcinoma | predicted - sensitive | Cisplatin + Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) and Platinol (cisplatin) combination treatment resulted in decreased tumor marker level within 1 month and disease stabilization with a progression-free survival of 12 months in a patient with hepatocellular carcinoma harboring FANCA Q1307Sfs*6 (PMID: 36181052). | 36181052 |
| BARD1 R565C | breast cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 R565C was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 G491R | ovarian cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 G491R was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 P187A | ovarian cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 P187A was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 P187A | breast cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 P187A was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 R150* | neuroblastoma | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Lynparza (Olaparib) and Platinol (cisplatin) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 R150* culture (PMID: 37688570). | 37688570 |
| BARD1 Q730L | breast cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 Q730L was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 P669L | ovarian cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 P669L was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 Q730L | ovarian cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 Q730L was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 R565C | ovarian cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 R565C was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 E287fs | neuroblastoma | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Lynparza (Olaparib) and Platinol (cisplatin) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 E287fs culture (PMID: 37688570). | 37688570 |
| BARD1 V85M | ovarian cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 V85M was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 P669L | breast cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 P669L was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 T719R | breast cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 T719R was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 R112* | neuroblastoma | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Lynparza (Olaparib) and Platinol (cisplatin) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 R112* culture (PMID: 37688570). | 37688570 |
| BARD1 T719R | ovarian cancer | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 T719R was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST